You are here

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Campbell, California, 95008 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
60-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Be of non-child bearing potential

- Diagnosis of dry AMD including uni- or multi-focal geographic atrophy without foveal
involvement

- BCVA of 20/50 or better in the study eye

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of ocular disease other than advanced AMD or GA in the study eye

- History or diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular
lesions in the study eye

- Presence of disease or condition that might compromise the cardiovascular,
hematological, renal, hepatic, pulmonary, endocrine, central nervous immune, or
gastrointestinal system

- Requires ocular or systemic medications that are known to be toxic to the lens, retina
or optic nerve

NCT01003691
Pfizer
Completed
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
NCT00902785
All Genders
50+
Years
Multiple Sites
Macular Degeneration
NCT00460408
All Genders
18+
Years
Multiple Sites
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
NCT00877032
All Genders
18+
Years
Multiple Sites
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
NCT01003691
All Genders
60+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now